Prognostic factors for response and survival of second-line chemotherapy in patients with relapsed small cell lung cancer (SCLC)

被引：0
|
作者：
Kim, Y. [1 ]
Goto, K. [1 ]
Yoh, K. [1 ]
Niho, S. [1 ]
Ohmatsu, H. [1 ]
Kubota, K. [1 ]
Saijo, N. [1 ]
Nishiwaki, Y. [1 ]
机构：
[1] Natl Canc Ctr Hosp East, Kashiwa, Chiba, Japan
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2007年 / 25卷 / 18期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
18023
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Second-Line Chemotherapy and Beyond for Non-Small Cell Lung Cancer
    Durm, Greg
    Hanna, Nasser
    HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA, 2017, 31 (01) : 71 - +
  • [32] Efficacy and safety of second-line (2L) therapy in patients with relapsed small cell lung cancer (SCLC): A systematic literature review (SLR).
    Nair, Abhishek A.
    Kwon, Christina S.
    Harricharan, Sharada
    Zhang, Xinke
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [33] Second-line nivolumab in relapsed small-cell lung cancer: CheckMate 331
    Spigel, D. R.
    Vicente, D.
    Ciuleanu, T. E.
    Gettinger, S.
    Peters, S.
    Horn, L.
    Audigier-Valette, C.
    Pardo Aranda, N.
    Juan-Vidal, O.
    Cheng, Y.
    Zhang, H.
    Shi, M.
    Luft, A.
    Wolf, J.
    Antonia, S.
    Nakagawa, K.
    Fairchild, J.
    Baudelet, C.
    Pandya, D.
    Doshi, P.
    Chang, H.
    Reck, M.
    ANNALS OF ONCOLOGY, 2021, 32 (05) : 631 - 641
  • [34] Docetaxel as second-line chemotherapy for non-small-cell lung cancer
    Roila, F
    Del Favero, A
    Ballatori, E
    JOURNAL OF CLINICAL ONCOLOGY, 2000, 18 (21) : 3738 - 3738
  • [35] The role of second-line chemotherapy in small cell lung cancer: a retrospective analysis
    Zarogoulidis, Konstantinos
    Boutsikou, Efimia
    Zarogoulidis, Paul
    Darwiche, Kaid
    Freitag, Lutz
    Porpodis, Konstantinos
    Latsios, Dimitrios
    Kontakiotis, Theodoros
    Huang, Haidong
    Li, Qiang
    Hohenforst-Schmidt, Wolfgang
    Kipourou, Maria
    Turner, J. Francis
    Spyratos, Dionysios
    ONCOTARGETS AND THERAPY, 2013, 6 : 1493 - 1500
  • [36] Phase II study of fenretinide in patients with small cell lung cancer (SCLC) with progression after first- or second-line chemotherapy.
    Schneider, BJ
    Worden, F
    Gadgeel, S
    Hodges, C
    Parchment, R
    Zwiebel, J
    Kraut, M
    Kalemkerian, G
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 690S - 690S
  • [37] A prognostic model for platinum-doublet as second-line chemotherapy in advanced non-small-cell lung cancer patients
    Mo, Hongnan
    Hao, Xuezhi
    Liu, Yutao
    Wang, Lin
    Hu, Xingsheng
    Xu, Jianping
    Yang, Sheng
    Xing, Puyuan
    Shi, Youwu
    Jia, Bo
    Wang, Yan
    Li, Junling
    Wang, Hongyu
    Wang, Ziping
    Sun, Yan
    Shi, Yuankai
    CANCER MEDICINE, 2016, 5 (06): : 1116 - 1124
  • [38] Combined Chemotherapy Versus Topotecan Monotherapy as Second-Line Treatment for Patients with Sensitive Relapsed SCLC
    Zhang, L.
    Liu, X.
    Cheng, Y.
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (12) : S1088 - S1088
  • [39] Pooled analysis of topotecan (T) in the second-line treatment of patients (pts) with sensitive small cell lung cancer (SCLC)
    Eckardt, J
    Depierre, A
    Ardizzoni, A
    VonPawel, J
    Fields, S
    EUROPEAN JOURNAL OF CANCER, 1997, 33 : 1041 - 1041
  • [40] Second-line treatment of small cell lung cancer
    Schmittel, A.
    Sebastian, M.
    Niederle, N.
    ONKOLOGE, 2013, 19 (11): : 940 - +
12345